Clinical trials: Ocular Hypertension
Normal Subject, Glaucoma
Assessment of an Automated Optical Coherence Tomography and Camera : Effectiveness of Vision-700
The objective of study is to assess the repeatability and agreement of the retina and cornea measurement by Vision-700 in comparison with those by 3D OCT-1.
- Conditions
- Normal Subject, Glaucoma, Retinal Disease, Cornea
- Trial name
- NCT06496763
- Testing
- Vision-700
- Where
- Taiwan
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Crystalvue Medical Coporation
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction
This non-inferiority study will assess safety and efficacy of LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) versus DuoTrav® (travoprost 0.004%/timolol 0.5% combination ophthalmic solution) in patients previously on…
- Trial name
- NCT01547598
- Testing
- travoprost ophthalmic solution 0.004%, travoprost 0.004% / timolol 0.5% combination ophthalmic solution, Bimatoprost ophthalmic solution 0.01%
- Where
- Canada
- Volunteers
- 135 people
- Sponsor
- Allergan
Glaucoma, Open Angle or Ocular Hypertension
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide compared with AzoptTM
- Trial name
- NCT03896633
- Testing
- brinzolamide 1% ophthalmic suspension, Azopt 1%
- Where
- United States
- Volunteers
- 637 people
- Sponsor
- Bausch & Lomb Incorporated
Glaucoma, Ocular Hypertension
Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular Hypertension
Subjects are dosed twice daily at 9AM and 9PM for 12 weeks. The primary efficacy variable is the mean change in Intraocular Pressure (IOP) from baseline to 12 weeks.
- Trial name
- NCT01111890
- Testing
- Azarga (brinzolamide 1% / timolol 0.5%), Cosopt (dorzolamide 2% / timolol 0.5%)
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Alcon Research
Glaucomas, Pterygium
Ologen(Oculusgen)-Glaucoma and Pterygium Historical Control Study in China Shanghai Sixth People's Hospital
The purpose of this study is to determine whether the ologen (OculusGen) Collagen Matrix are effective and safe to implant as an aid of glaucoma surgery and pterygium excision surgery.
- Trial name
- NCT00478790
- Testing
- ologen™ Collagen matrix implantation in glaucoma filtering surgery
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Pro Top & Mediking Company Limited
Glaucoma, Open-Angle
H-1337 Ophthalmic Solution Phase 1/2
The study will evaluate the safety, tolerability, and preliminary efficacy of three concentrations of H-1337 and vehicle administered twice daily in a parallel group, double-masked design for 28 days of dosing in patients with…
- Trial name
- NCT03452033
- Testing
- H-1337 [1], H-1337 [2], H-1337 [3]
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Allysta Pharmaceutical
Open-angle Glaucoma, Ocular Hypertension
A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs
The objective of the study was to evaluate whether timolol hemihydrate is more comfortable upon instillation than timolol maleate in sorbate. This was an observational study.
- Trial name
- NCT00823043
- Testing
- timolol hemihydrate, timolol maleate
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Vistakon Pharmaceuticals
Open-angle Glaucoma, Ocular Hypertension
Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to investigate the safety and efficacy of five concentrations of DE-117 ophthalmic solution.
- Trial name
- SEE-1 (NCT02179008)
- Testing
- DE-117 Low Dose ophthalmic solution, DE-117 Low/Middle Dose ophthalmic solution, DE-117 Middle Dose ophthalmic solution
- Where
- 14 sites in United States
- Volunteers
- 184 people
- Sponsor
- Santen Inc.
Glaucoma, Ocular Hypertension
Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.
This study is designed as an open label evaluation of the efficacy of latanoprost and timolol fixed combination (Xalacom) after 6 month of treatment. Eligible patients may be enrolled at the baseline visit.
- Trial name
- NCT00143208
- Testing
- Xalacom
- Where
- 21 sites in Italy
- Volunteers
- 250 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open Angle Glaucoma, Ocular Hypertension
Study of a Latanoprost Ocular Implant for Treatment of Open Angle Glaucoma or Ocular Hypertension.
This is an open label, single dose (100 ng/day) study to assess the safety, tolerability and biodegradation of the PA5436 Latanoprost FA SR Ocular Implant in adults who have OAG or OHT.
- Trial name
- NCT05333419
- Testing
- 100ng/day PA5346 Latanoprost FA SR Ocular Implant
- Where
- 2 sites in New Zealand
- Volunteers
- 1 people
- Sponsor
- PolyActiva Pty Ltd
Glaucoma, Open-Angle, Ocular Hypertension
Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device
Compare the antihypertensive efficacy of two methods for instilling Xalatan eyedrops
- Trial name
- NCT00283764
- Testing
- Xalatan
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary Open Angle Glaucoma
The Effects of Visior on Ocular Hemodynamics
To determine the relationship between the affects of viewing commercially available content through the VISIOR video goggles and ocular blood flow in glaucoma patients and healthy subjects.
- Trial name
- NCT02959593
- Testing
- VISIOR video goggles
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Visior Technologies Ltd.
Glaucoma, Neovascular
Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients
To assess the efficacy and safety of the administration of aflibercept by intravitreal injection in comparison to sham to control intraocular pressure in patients with neovascular glaucoma.
- Trial name
- VEGA (NCT02396316)
- Testing
- Aflibercept (Eylea, BAY 86-5321)
- Where
- 19 sites in Japan
- Volunteers
- 54 people
- Sponsor
- Bayer
Open Angle Glaucoma, Ocular Hypertension
Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH
This study is a double-masked, randomized, parallel group study in patients with open angle glaucoma or ocular hypertension. The aim of this study is to verify the efficacy of the fixed combination of Latanoprost 50 mcg / mL /…
- Trial name
- NCT01721707
- Testing
- Latanoprost+Brinzolamide combination, Latanoprost
- Where
- Brazil
- Sponsor
- Adapt Produtos Oftalmológicos Ltda.
Primary Open-angle Glaucoma
Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry
The purpose of this study is to observe the safety of the Glaukos® iStent® Trabecular Micro-Bypass Stent Model GTS100 in conjunction with cataract surgery in subjects with mild to moderate open-angle glaucoma.
- Trial name
- NCT01841437
- Testing
- iStent
- Where
- 18 sites in United States
- Volunteers
- 191 people
- Sponsor
- Glaukos Corporation
Open Angle Glaucoma, Ocular Hypertension
Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension
The goal of this clinical trial is to learn about the safety of Travoprost Ophthalmic Topical Cream and how well it works in lowering high intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular…
- Trial name
- NCT06152861
- Testing
- Travoprost Ophthalmic Topical Cream low-dose, Travoprost Ophthalmic Topical Cream mid-dose, Travoprost Ophthalmic Topical Cream high-dose
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Glaukos Corporation
Open Angle Glaucoma, Ocular Hypertension
Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension
A single-blind , 12-week, parallel group clinical study is planned to evaluate the efficacy and safety of SPARC0912 and Reference0912.
- Trial name
- NCT00947661
- Testing
- SPARC0912, Reference0912
- Where
- United States
- Volunteers
- 578 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Healthy Volunteers
Safety and Tolerability of NTX-101 in Korean Healthy Volunteers
A double-blinded, placebo controlled, multiple dose, randomized, single site, phase 1 clinical trial to evaluate safety, tolerability, and pharmacokinetics of NTX-101 topical eye drop in Korean healthy volunteers
- Trial name
- NCT05041543
- Testing
- NTX-101
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pinotbio, Inc.
Glaucoma, Age Related Macular Degeneration
Assessment of Visual Function With a Portable Brain-computer Interface
1. The purpose of this study is to evaluate the nGoggle's accuracy and repeatability in detecting visual function loss. In addition, the ability to stage glaucomatous damage and investigate the relationship between nGoggle…
- Conditions
- Glaucoma, Age Related Macular Degeneration, Optic Neuropathy, Retinal Degeneration
- Trial name
- NCT03760055
- Testing
- nGoggle
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- NGoggle
Glaucoma
A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients
The primary objective of the clinical study is to evaluate the efficacy and safety for Mikelan LA eye drops 2% (once per day) of intra-ocular pressure decreased.
- Trial name
- NCT00972426
- Testing
- carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)
- Where
- Taiwan
- Volunteers
- 32 people
- Sponsor
- Taiwan Otsuka Pharm. Co., Ltd